Hematologic Malignancies Market
- 2026 年市場規模
- USD 90.02 Bn
- 2033 年預估規模
- USD 179.64 Bn
- 年複合成長率 CAGR
- 10.2%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Hematologic Malignancies Market, By Type (Leukemia (Acute Leukemias, (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)), Chronic Leukemias (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Others (Hairy Cell Leukemia, etc.))), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL)), Plasma Cell Dyscrasias (Multiple Myeloma, Smoldering Multiple Myeloma, Others (Plasma Cell Leukemia, etc.)), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), and Others (Overlap Myeloid Neoplasms (MDS/MPN), etc.)), By Age Group (Pediatric, Adult, and Geriatric), By Treatment Modality (Conventional chemotherapy (Alkylating agents, Antimetabolites, Others (Anthracyclines, etc.), Targeted therapies, (Tyrosine kinase inhibitors (e.g., BCR-ABL inhibitors), BCL-2 inhibitors, BTK inhibitors, Others (PI3K inhibitors, etc.)), Immunomodulatory drugs (IMiDs), Proteasome inhibitors, Epigenetic/differentiation agents, Monoclonal antibodies, Bispecific antibodies / T-cell engagers, and Others (Antibody-drug conjugates (ADCs), etc.)), By Route of Administration (Oral , Intravenous (IV) , Subcutaneous (SC) , and Others (Intramuscular (IM), etc.)), By Distribution Channel (Online and Offline), By End User (Hospitals , Cancer Centers , Ambulatory infusion centers , Homecare Settings , and Others (Academic and Research Institutes, etc.)), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)
報告摘要
According to Coherent Market Insights, the global hematologic malignancies market is estimated to be valued at USD 90.02 Bn in 2026 and is expected to reach USD 179.64 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 10.2% from 2026 to 2033. The global hematologic malignancies market represents a critical segment within the oncology therapeutics landscape, encompassing a diverse range of blood cancers including leukemia, lymphoma, and multiple myeloma. These malignancies originate in the blood-forming tissues, primarily affecting the bone marrow, lymph nodes, and other components of the lymphatic system. The market has witnessed substantial growth driven by increasing disease prevalence, particularly among aging populations, coupled with significant advancements in diagnostic technologies and therapeutic interventions.
Innovative treatment modalities such as CAR-T cell therapies, monoclonal antibodies, and targeted therapies have revolutionized patient outcomes, creating new revenue streams for pharmaceutical companies. The market encompasses various therapeutic approaches including chemotherapy, immunotherapy, stem cell transplantation, and novel precision medicine solutions. Rising healthcare expenditure, improved access to specialized oncology care, and enhanced early detection capabilities have further propelled market expansion. Additionally, the development of personalized medicine approaches based on genetic profiling and biomarker identification has opened new therapeutic avenues. The market's complexity is characterized by diverse disease subtypes, varying treatment protocols, and the emergence of combination therapies that offer improved efficacy profiles, positioning it as a high-value segment within the broader oncology market.
Market Dynamics
The global hematologic malignancies market is propelled by several key drivers that collectively fuel its robust growth trajectory. The primary driver stems from the increasing global incidence of blood cancers, particularly among elderly populations, with demographic shifts toward aging societies worldwide contributing to higher disease prevalence rates. Technological advancements in diagnostics, including next-generation sequencing, flow cytometry, and molecular testing, enable earlier detection and precise disease characterization, facilitating timely therapeutic interventions.
The revolutionary development of innovative therapies, particularly CAR-T cell treatments, bispecific antibodies, and checkpoint inhibitors, has dramatically improved patient outcomes and created substantial market value. Growing healthcare infrastructure in emerging markets and increased healthcare spending globally have expanded patient access to specialized treatments. However, the market faces significant restraints including the extremely high costs associated with novel therapies, particularly CAR-T treatments that can exceed USD 400,000 per patient, creating affordability challenges for healthcare systems and patients. Stringent regulatory approval processes for complex cellular therapies and biologics often result in lengthy development timelines and substantial investment requirements before market entry.
Additionally, the complexity of treatment protocols and the need for specialized healthcare facilities and trained personnel limit widespread adoption in certain regions. Despite these challenges, substantial opportunities exist in the development of next-generation therapies with improved safety profiles, the expansion of treatment applications to earlier disease stages, and the growing potential for combination therapies that enhance therapeutic efficacy while potentially reducing individual drug costs and treatment duration.
Key Features of the Study
• This report provides in-depth analysis of the global hematologic malignancies market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hematologic malignancies market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb, Roche, Novartis, AbbVie, Amgen, Celgene, Gilead Sciences, Johnson & Johnson, Sanofi, Merck & Co., Pfizer, Eli Lilly and Company, Takeda Pharmaceutical Company, GSK, and Regeneron Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global hematologic malignancies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hematologic malignancies market
Market Segmentation
• Type Insights (Revenue, USD Bn, 2021 - 2033)
o Leukemia
Acute Leukemias
o Acute Myeloid Leukemia (AML)
o Acute Lymphoblastic Leukemia (ALL)
Chronic Leukemias
o Chronic Myeloid Leukemia (CML)
o Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
o Others (Hairy Cell Leukemia, etc.)
o Lymphoma
Hodgkin Lymphoma
Non-Hodgkin Lymphoma (NHL)
o Plasma Cell Dyscrasias
Multiple Myeloma
Smoldering Multiple Myeloma
Others (Plasma Cell Leukemia, etc.)
o Myelodysplastic Syndromes (MDS)
o Myeloproliferative Neoplasms (MPN)
o Others (Overlap Myeloid Neoplasms (MDS/MPN), etc.)
• Age Group Insights (Revenue, USD Bn, 2021 - 2033)
o Pediatric
o Adult
o Geriatric
• By Treatment Modality Insights (Revenue, USD Bn, 2021 - 2033)
o Conventional chemotherapy
Alkylating agents
Antimetabolites
Others (Anthracyclines, etc.)
o Targeted therapies
Tyrosine kinase inhibitors (e.g., BCR-ABL inhibitors)
BCL-2 inhibitors
BTK inhibitors
Others (PI3K inhibitors, etc.)
o Immunomodulatory drugs (IMiDs)
o Proteasome inhibitors
o Epigenetic / differentiation agents
o Monoclonal antibodies
o Bispecific antibodies / T-cell engagers
o Others (Antibody-drug conjugates (ADCs), etc.)
• Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
o Oral
o Intravenous (IV)
o Subcutaneous (SC)
o Others (Intramuscular (IM), etc.)
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
o Online
o Offline
• End User Insights (Revenue, USD Bn, 2021 - 2033)
o Hospitals
o Cancer Centers
o Ambulatory infusion centers
o Homecare Settings
o Others (Academic and Research Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o Bristol-Myers Squibb
o Roche
o Novartis
o AbbVie
o Amgen
o Celgene
o Gilead Sciences
o Johnson & Johnson
o Sanofi
o Merck & Co.
o Pfizer
o Eli Lilly and Company
o Takeda Pharmaceutical Company
o GSK
o Regeneron Pharmaceuticals
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Global Hematologic Malignancies Market, By Type
Global Hematologic Malignancies Market, By Age Group
Global Hematologic Malignancies Market, By Treatment Modality
Global Hematologic Malignancies Market, By Route of Administration
Global Hematologic Malignancies Market, By Distribution Channel
Global Hematologic Malignancies Market, By End User
Global Hematologic Malignancies Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Key Developments
o Industry Trends
4. Global Hematologic Malignancies Market, By Type, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Leukemia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Acute Leukemias
o Acute Myeloid Leukemia (AML)
o Acute Lymphoblastic Leukemia (ALL)
Chronic Leukemias
o Chronic Myeloid Leukemia (CML)
o Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
o Others (Hairy Cell Leukemia, etc.)
o Lymphoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Hodgkin Lymphoma
o Non-Hodgkin Lymphoma (NHL)
o Plasma Cell Dyscrasias
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Multiple Myeloma
o Smoldering Multiple Myeloma
o Others (Plasma Cell Leukemia, etc.)
o Myelodysplastic Syndromes (MDS)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Myeloproliferative Neoplasms (MPN)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others (Overlap Myeloid Neoplasms (MDS/MPN), etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Hematologic Malignancies Market, By Age Group, 2021-2033, (USD Bn)
Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Pediatric
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Adult
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Geriatric
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Hematologic Malignancies Market, By Treatment Modality, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Conventional chemotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Alkylating agents
o Antimetabolites
o Others (Anthracyclines, etc.)
o Targeted therapies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Tyrosine kinase inhibitors (e.g., BCR-ABL inhibitors)
o BCL-2 inhibitors
o BTK inhibitors
o Others (PI3K inhibitors, etc.)
o Immunomodulatory drugs (IMiDs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Proteasome inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Epigenetic / differentiation agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Monoclonal antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Bispecific antibodies / T-cell engagers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others (Antibody-drug conjugates (ADCs), etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Hematologic Malignancies Market, By Route of Administration, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Intravenous (IV)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Subcutaneous (SC)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others (Intramuscular (IM), etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Hematologic Malignancies Market, By Distribution Channel, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Online
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Offline
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
9. Global Hematologic Malignancies Market, By End User, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Cancer Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Ambulatory infusion centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Homecare Settings
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others (Academic and Research Institutes, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
10. Global Hematologic Malignancies Market, By Region, 2021 - 2033, Value (USD Bn)
o Introduction
Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
Regional Trends
o North America
Introduction
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
o South Africa
o North Africa
o Central Africa
11. Competitive Landscape
o Bristol-Myers Squibb
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Roche
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Novartis
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o AbbVie
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Amgen
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Celgene
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Gilead Sciences
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Johnson & Johnson
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Sanofi
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Merck & Co.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Pfizer
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Takeda Pharmaceutical Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o GSK
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Regeneron Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
12. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
13. References and Research Methodology
o References
o Research Methodology
o About us
*Browse 32 market data tables and 28 figures on 'Hematologic Malignancies Market' - Global forecast to 2033
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們